{"entity":{"id":"idea-pv-clone-directed-therapy","kind":"idea","name":"Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission","aka":[],"tldr":"Today's PV drugs control blood counts but leave the mutant cells in place. Interferon is the one treatment that shrinks the clone, and the first JAK2 V617F-selective inhibitors have entered trials; combining the two could aim at molecular remission, the way imatinib did for CML.","summary":"Polycythaemia vera is driven by a single recurrent mutation in almost every patient, yet no treatment is given with the aim of eliminating it. Ropeginterferon alfa-2b lowers the JAK2 V617F allele burden year on year in PROUD-PV and CONTINUATION-PV, and a fraction of patients reach very low burdens. Ruxolitinib blocks wild-type and mutant JAK2 alike, which limits its dose and spares the clone. Mutant-selective JAK2 V617F inhibitors are now in first-in-human trials. The idea is to test interferon plus a mutant-selective inhibitor against interferon alone with molecular response and progression, not haematocrit, as the endpoints.","asOf":"2026-09-16","links":[],"tags":["polycythaemia-vera","mpn"],"related":[],"cancers":["polycythaemia-vera","myeloproliferative-neoplasms"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["jak2"],"drugs":["ropeginterferon-alfa-2b","ruxolitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["proud-pv","majic-pv"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hypothesis":"Ropeginterferon alfa-2b combined with a JAK2 V617F-selective inhibitor will produce deep molecular responses (allele burden below 1 percent) in a majority of patients within three years, and deep responders will have a lower rate of progression to myelofibrosis than count-controlled patients.","rationale":"Interferon's molecular responses are durable and associated with fewer events; complete responders in MAJIC-PV had better event-free survival; CML showed that a single-driver disease can be pushed to treatment-free remission once the clone is suppressed deeply enough.","test":"A randomised phase 2 in high-risk PV: ropeginterferon with or without a mutant-selective JAK2 inhibitor once phase 1 doses are set, with JAK2 V617F allele burden at 24 and 36 months as the primary endpoint and progression, thrombosis and treatment discontinuation as secondary endpoints.","maturity":"early-clinical","actor":"industry","cost":"large","horizonYears":7},"route":"/ideas/idea-pv-clone-directed-therapy/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"trial":[{"id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/"},{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/"}]}}